

# Quarterly Report 2007

September 30, 2007



# Letter to our Stockholders

Dear Stockholders,

The third quarter 2007 was certainly a surprise with respect to the growth in sales and the increase in operating result. The substantial increases are to be evaluated as extremely positive against the background of higher project preparatory services and a continued great number of orders on the books. In addition, we have been able to improve our good position in quality management of hospitals with the acquisition of Holl GmbH in the current quarter.

2

During the first nine months of the current year, the activities of NEXUS AG have concentrated very strongly on implementing customer projects and adapting corporate structures to the development of sales. The growth, internationalization acquisitions and innovation projects require numerous organizational measures. Our essential task in this is to orient the potential of the company to product quality and customer satisfactions and to increase the ability of the organization to perform. This is the only way to ensure that the successes of the past will continue in the long term. For this year, we are going to continue to focus on this potential as well as innovation and increasing sales in 2007 and 2008 too. We are only going to concentrate on improving revenues as a secondary matter.

We will be judged by how reliably and on-time we handle our orders and consequently can establish a basis for future expansion. We are challenged to work even more professionally to handle our tasks in the areas of service and project implementation and consequently generate customer satisfaction. The same applies as previously: customers trust us and expect highly professional solutions with advanced technology and contents to optimize their hospital processes. These are challenges, which we are glad to face.

## Highlights first three Quarters - 2007 Business development

- + Very strong increase in sales and profit
- + Additional new contracts in third quarter
- + Orientation of the organization to service structures
- + Strengthening of our position in the area of quality management

**Against the background of these challenges, we are that much more pleased that we have been able to surpass our expectations by far and achieve high growth figures both in sales and operating result.**

We have also been able to continue our success of the past months in the area of new orders and still have a lot of orders on our books as previously.

As a result, we have created an excellent basis during the first three quarters to achieve our ambitious goals of the current year. We have again been able to strengthen the position of our company substantially with our acquisitions and market successes and can look to the remaining quarter 2007 with optimism.

We were able to continue the uninterrupted positive development of the past 21 quarters in the third quarter this year. For the 21st time in a row, sales and operating result were higher than the comparative quarter of the previous year.

**Sales increased by approximately 30%** in the current quarter 2007 compared to the same quarter of the previous year and rose to **approximately 8.1 million €** following 6.1 million € in Q3 2006. In the first nine months, **sales amounted to approx. 21.4 million € following 17.1 million € in 2006 (+25%).**

3

**The Healthcare Software segment was again strong and was able to increase by about 30% to approx. 18.5 million € (Q3-2006: 14.2 million €).**

The Group result also developed very well during the first nine months. The **EBTDA rose to approx. 4.5 million € following 3.4 million €** in the first 3 quarters of the previous year **(+34%)**. The **result** before taxes improved from **KEUR 1.493 following KEUR 736 by about 103%** and an improvement after taxes of approx. 80% was achieved.

In spite of these outstanding figures, we are aware that we are facing considerable challenges in our new projects until the end of the year. Many projects have to be developed to a defined stated and be accepted. But we are working on these tasks with a very skilled staff and high motivation and will use the remaining time to fulfill requirements.

Sincerely,



Dr. Ingo Benndt  
CEO - NEXUS AG




# Innovations: Strong Dedication to Quality Management in Hospitals

NEXUS has increased its involvement in the area of quality management systems further with the acquisitions of the Holl GmbH on 28 August 2007. Our objective is to link the topics of quality management, knowledge management and medical documentation in one product world.

4

Holl GmbH supports certification procedures of KTQ, ProCum Cert and EFQM for approximately 400 customers using the software tool „AssessmentGuide“.

At the same time, NEXUS has an excellent knowledge database for quality management in hospitals with NEXUS / CURATOR. Thanks to the combination of both products, a solution from one source has been created for the first time with which the complete control circuit of quality management can be closed.



**From self-assessment to assessment by third parties and all the way to knowledge-based management of the QM systems, NEXUS provides a software solution complete in itself that relieves the burden of many administrative problems of certification for users.**

The combination with the medical applications of NEXUS is outstanding in this context. QM information is available to doctors and nurses for patient documentation online and context-related. This makes it possible to combine patient-related and organizational quality requirements consistently.

In collaboration with KTQ GmbH, NEXUS is using the acquisition of Holl GmbH to increase its involvement in quality management in hospitals visibly and support hospitals actively in this area.

# NEXUS in the environment of Financial and Health markets



The price of NEXUS stocks rose to a provisional high of approx. 4 € at the beginning of August. From the middle of August until the middle of November, the price fell to approx. 3 € with intermediate lateral movements around 3.50 €.

The stock repurchasing program started on 1 November 2007 is having a positive effect on the NEXUS stock price. The stocks suffered due to the general negative trend in the market at the time of publishing the Q3 report.

## Finance- and Event schedule 2007/2008 (status quo: November '07)

### Finance schedule

Annual Report 2007	March 25, 2008
Analyst Conference, Frankfurt	March 31, 2008

### Event and trade fair schedule

DGPPN, Berlin	November 21. - 24.
Dt. Kongress für Perinatale Medizin, Berlin	11/29/07 - 12/01/07
Arab Health 2008, Dubai (U.A.E)	January 28 - 31, 2008

5

## Decisions for NEXUS-solutions 2007

- + Schmieder Kliniken, Allensbach (D)
- + Zentrum für Radiologie und Nuklearmedizin, Bad Godesberg (D)
- + Deutsches Herzzentrum, Berlin (D)
- + Vivantes-Auguste-Viktoria-Klinikum, Berlin (D)
- + Kliniken Landkreis Biberach, Biberach (D)
- + Klinikum, Darmstadt (D)
- + Kath. Kliniken, Duisburg (D)
- + Universitätsfrauenklinik, Freiburg (D)
- + Neurologisches Reha Zentrum, Greifswald (D)
- + Kreiskrankenhaus, Groß-Umstadt (D)
- + Diakonie-Krankenhaus, Ingelheim (D)
- + Westpfalz-Klinikum, Kaiserslautern (D)
- + Zentrum für Rad. und Nuklearmed., Karlsruhe (D)
- + Pfalz-Klinikum, Klingenmünster (D)
- + Krankenhaus, Leonberg (D)
- + Klinikum, Neunkirchen (D)
- + Luisenkrankenhaus, Lindenfels (D)
- + Chirurgische Klinik Dr. Rinecker, Munich (D)
- + Diakonie-Krankenhaus, Rotenburg (Wümme) (D)
- + Thüringen-Klinik - Saalfeld, Pöbneck (D)
- + Krankenhaus, Porz (D)
- + Thüringen-Kliniken - Saalfeld, Rudolstadt (D)
- + Klinikum, Saarbrücken (D)
- + DGD Krankenhaus, Sachsenhausen (D)
- + Kreiskrankenhaus, Seeheim-Jugenheim (D)
- + DRK Krankenhaus, Teterow (D)
- + Anna-Henrietten-Stift, Traben-Trarbach (D)
- + Uni-Klinik, Tübingen (D)
- + Evang. Krankenhaus Hochstift, Worms (D)
- + Krankenanstalten Verbund (KAV), Wien (A)
- + AZ Sint-Blasius, Dendermonde (B)
- + St. Josef Klinik, St. Vith (B)
- + Krankenhaus Sheinovo, Sofia (BG)
- + Kantonsspital, Aarau (CH)
- + Spital, Altstätten (CH)
- + Universitätsspital, Basel (CH)
- + Spital, Flawil (CH)
- + Spital, Grabs (CH)
- + Spital, Linth-Utznach (CH)
- + Kantonsspital, Luzern (CH)
- + Spital, Rorschach (CH)
- + Bürgerspital, St. Gallen (CH)
- + Kantonsspital, St. Gallen (CH)
- + Luzerner Psychiatrie, St. Urban (CH)
- + Spital, Walenstadt (CH)
- + Spital, Wattwil (CH)
- + Spital, Wil (CH)
- + Klinik Hirslanden, Zurich (CH)
- + Centre Hospitalier Emile Mayrisch, Esch-sur-Alzette (LU)


# Sales and Operating Result Increase in the 3rd Quarter

In first three quarters of 2007, sales of Nexus Group increased by 25.0% from KEUR 17,110 to KEUR 21,389. While segment sales in „Healthcare Service“ almost remained the same at KEUR 2,939 (previous year: KEUR 2,938), sales in the „Healthcare Software“ segment increased from KEUR 14,172 by KEUR 4,278 to KEUR 18,450 (+30.2%).

In the „Healthcare Software“ segment, sales even increased **by KEUR 2,307 (+45.5 %) from KEUR 5,072 to KEUR 7,379** in the third quarter compared to the previous year. On the other hand, quarterly sales decreased by 22.7% **from KEUR 997 to KEUR 771** in the „Healthcare Service“ segment.

6

**Foreign sales rose by KEUR 3,504 from KEUR 5,440 in the previous year to KEUR 8,944 (+64.4%) during the first nine months.**



Sales in the Middle East and Switzerland contributed decisively to these sales increases. The sales increase of 66.0% in Switzerland is partially due to inclusion of NEXUS Schweiz GmbH in the figures. The **foreign share of sales was 41.81%** on the cutoff date.

**Domestic sales increased by 6.6%** from KEUR 11,670 to **KEUR 12,445** despite unchanged sales figures in the „Healthcare Service“ sector.

## Sales by regions

	01/01/ -	01/01/ -	Δ in %	07/01/ -	07/01/ -	Δ in %
	09/30/06	09/30/07		09/30/07	09/30/07	
	TEUR	TEUR		TEUR	TEUR	
Germany	11,670	12,445	6.6	3,725	4,731	27.0
Switzerland	3,737	6,205	66.0	1,778	1,915	7.7
Austria	374	730	95.1	34	223	555.8
Italy	252	127	-49.6	187	39	-79.1
Rest of world / USA	1,077	1,882	74.7	345	1,242	260.0
<b>Total</b>	<b>17,110</b>	<b>21,389</b>	<b>25.0</b>	<b>6,069</b>	<b>8,150</b>	<b>34.3</b>

## Highlights 3. Quarter - 2007 Group sales and Result

- + 25.0 % sales increase from KEUR 17,110 (Q3-2006) to KEUR 21,389 during the first three quarters 2007
- + 30.2% sales increase from KEUR 14,172 (Q3-2006) to KEUR 18,450 in the Healthcare Software area
- + 80% increase in result before taxes from KEUR 592 (Q3-2006) to KEUR 1,065
- + Cash reserves decreased to 12.1 million € due to company acquisitions
- + Large number of orders received

## Sales by divisions

	01.01. -	01.01. -	Δ in %	01.07. -	01.07. -	Δ in %
	30.09.06	30.09.07		30.09.06	30.09.07	
	TEUR	TEUR		TEUR	TEUR	
Healthcare Software	14,172	18,450	30.2	5,072	7,379	45.5
Healthcare Service	2,938	2,939	0.0	997	771	-22.7
<b>Total</b>	<b>17,110</b>	<b>21,389</b>	<b>25.0</b>	<b>6,069</b>	<b>8,150</b>	<b>34.3</b>




# Results in the First three Quarters 2007

The positive development of results is continuing. In the first three quarters 2007, the Group result improved by 79.9% from KEUR 592 to KEUR 1,065. The result before taxes improved even more by KEUR 757 from KEUR 736 in the previous year to KEUR 1,493 (+102.8%).

Thanks to the positive development of sales, the **EBTDA** was at **KEUR 4,480**, which corresponds to an increase of **KEUR 1,126 (+33.5%)** compared to the same period (**KEUR 3,354**) in the previous year.


The „**Healthcare Software**“ segment with **KEUR 962** (previous year: KEUR 647 / + 48.7%) and the „**Healthcare Service**“ segment with **KEUR 103** (previous year: KEUR 89 / +15.7%) contributed to the positive development of sales.

The **cash flow from current business transactions** was influenced essentially by the considerable increase of the period surplus as well as write-offs.




**Compared to the previous year, the cash flow increased by KEUR 418 from KEUR 1,518 to KEUR 1,936 (+27.5%).**

The **cash flow from investment activities** reflects payouts in intangible assets, fixed assets and financial assets, which will serve for future cash flows. NEXUS Group realized a cash flow of **KEUR -2,313 from KEUR -3,509** in the previous year. Purchase of NEXUS / PASCHMANN GmbH and NEXUS / HOLL GmbH represent the most important investments here, which were financed in part by the sale of securities. NEXUS Group continues to have **substantial cash reserves of KEUR 12,132**.



Number of employees developed like follows: see chart below.



# NEXUS Group informationen and Outlook

## Director's Holdings

The Director's Holdings of the supervisory board and the executive board were as follows on September 30, 2007 in comparison to the previous year:

## Outlook

The strong upward trend of our business over the past years was even accelerated in the third quarter. In spite of clearly focusing on growth and innovation, we have succeeded in improving results continually and even considerably in the last quarter. We are proud of these developments, which have taken place in an extremely competitive and complex environment.

A lot of things speak in favor of us being able to use our good market position and outstanding technology for unrestricted continuation of our series of successes. But substantial challenges remain for the remaining months in 2007 and the coming years, which we have to surmount. We have to adapt our project and service structures to our current business volume and push forward innovation and sales without any restrictions at the

same time. We are currently creating the basis for future expansion and economic success.

We are confident that we can also achieve our annual targets in 2007 and start 2008 with interesting orders on our books and again a good outlook for revenues. In the remaining weeks of this year, it will be a question of creating the prerequisites for acceptances by 31 Dec. 2007 and providing our customers with good products and services.

NEXUS is in an excellent position and can face these challenges with confidence. Large amount of orders on hand, good technology and a motivated staff: our development till now makes us confident that we will have success with these prerequisites.

## ACCOUNTING AND VALUATION METHODS

This interim report from the NEXUS Group of 30 September 2007 has been prepared in keeping with the International Financial Reporting Standards (IFRS) as they are applied in the EU. The interpretation of the International Financial Reporting Interpretation Committee (IFRIC) has been taken into account.

The regulations of IAS 34 have been observed in the interim report of 30 September 2007. This refers to a summarized report, which does not contain all information of an IFRS Group Financial Statement, and consequently this report should be read in connection with the Appendix of the Group Financial Statement 2006. The same accounting and valuation methods were used in the Group Financial Statement for the business year 2006.

The report has not been audited.

The Group Financial Statement 2006 and the interim report of 30 September 2007 can be seen on the homepage in the Internet at: [www.nexus-ag.de](http://www.nexus-ag.de).

Director's Holdings	Numbers of stocks owned	Numbers of options
<b>Supervisory Board</b>		
Dr. jur. Hans-Joachim König	81.099	0
	Prev. year: 81.099	0
Prof. Dr. Alexander Pocsay	0	0
	Previous year: 0	0
Ronny Dransfeld	0	0
	Previous year: 0	0
Prof. Dr. Ulrich Krystek	0	0
	Previous year: 0	0
Dipl.-Betriebsw. (FH) Wolfgang Dörflinger	0	0
	Previous year: 0	0
Dr. Dietmar Kubis	0	0
	Previous year: 0	0
<b>Executive Board</b>		
Dr. Ingo Behrendt (MBA)	82.000	325.000
	Prev. year: 82.000	340.000
Dipl.-Betriebsw. (FH) Stefan Burkart	116.147	15.000
	Prev. year: 116.147	0



# Facts and Figures Group P+L Account as of 09/30/2007 and 09/30/2006 (IFRS)

CONSOLIDATED PROFIT AND LOSS ACCOUNT	07/01/ - 09/30/06	07/01 - 09/30/07	01/01/ - 09/30/06	01/01/ - 09/30/07
	KEUR	KEUR	KEUR	KEUR
1. Revenue	6,069	8,150	17,110	21,389
2. Increase / decrease in finished goods and work in progress	-10	61	-54	101
3. Other capitalized company work	945	1,069	2,623	2,941
4. Other operating income	633	-27	1,008	565
5. Cost of materials	1,190	1,752	3,615	4,631
a) Cost of raw materials and supplies	607	1,450	2,637	3,961
b) Cost for purchased services	583	302	978	670
6. Personnel expenses	3,827	4,337	9,998	12,360
a) Wages and salaries	3,257	3,692	8,447	10,549
b) Social costs	570	645	1,551	1,811
7. Depreciation and amortization of fixed intangible and tangible assets	893	1,053	2,645	3,060
8. Other operating expenses	1,653	1,340	4,151	3,949
a) Cost of operation	-	358	-	1,097
b) Cost of distribution	-	384	-	1,157
c) Cost of administration	-	539	-	1,529
d) Other expenses	-	59	-	166
9. Other taxes	2	3	8	8
10. Expenses from associated companies	-	-	-	-
11. Other interest and similar income	108	120	477	509
12. Revenue from associated companies	-	3	-	3
13. Profit resulting from sale of other stocks	-	-	-	-
14. Depreciation of financial assets and losses resulting from the sale of assets	-	-	-	-
15. Interest payable and other similar charges	8	3	11	7
<b>PROFIT BEFORE TAX</b>	<b>172</b>	<b>888</b>	<b>736</b>	<b>1,493</b>
16. Income taxes	-41	-377	-144	-428
<b>ANNUAL NET PROFIT</b>	<b>131</b>	<b>511</b>	<b>592</b>	<b>1,065</b>
Are attributable to:				
Minority interest	-17	-2	-35	-80
Stockholders of parent company	114	509	557	985
Weighted average of issued shares (in thousands)	13,720	13,805	13,720	13,786
<b>ERESULT PER SHARE IN EUR (DILUTED AND UNDILUTED )</b>	<b>0.01</b>	<b>0.04</b>	<b>0.04</b>	<b>0.07</b>

# Facts and Figures

## Balance sheet as of 12/31/2007 and 09/30/2006 (IFRS)

10

<b>BALANCE SHEET AS OF 09/30/2007 (IFRS)</b>	<b>12/31/2006</b>	<b>09/30/2007</b>
<b>ASSETS</b>		
	<b>KEUR</b>	<b>KEUR</b>
<b>LONG-TERM CAPITAL</b>		
I. Intangible assets		
1. Concessions, industrial property rights, and rights and assets as well as licenses for such rights and assets	130	637
2. Goodwill	7,749	10,757
3. Development costs	8,311	8,810
4. Customer Base / Technology	2,656	2,743
II. Property, plant and equipment		
1. Tenant installations	5	5
2. Other equipment, factory and office equipment	689	866
III. Financial assets		
1. Investments in associates	48	48
2. Other loans	40	40
3. Long-term securities	0	43
IV. Deferred taxes	4,559	3,747
<b>TOTAL LONG-TERM CAPITAL</b>	<b>24,187</b>	<b>27,696</b>
<b>SHORT-TERM CAPITAL</b>		
I. Inventories		
1. Raw materials and supplies	75	75
2. Work in progress	195	292
3. Finished goods	42	143
4. Down payment made	–	0
II. Receivables and other assets		
1. Trade receivables	7,175	9,793
2. Receivables from associated companies	11	12
3. Other assets	2,047	3,050
4. Tax refund claims	368	354
III. Securities	14,691	10,348
IV. Cash and cash equivalents	2,755	1,784
<b>TOTAL SHORT-TERM CAPITAL</b>	<b>27,359</b>	<b>25,851</b>

# Facts and Figures

## Balance sheet as of 12/31/2007 and 09/30/2006 (IFRS)

<b>BALANCE SHEET AS OF 09/30/2007 (IFRS) EQUITY AND LIABILITIES</b>	<b>12/31/2006</b>	<b>06/30/2007</b>
	<b>KEUR</b>	<b>KEUR</b>
<b>EQUITY</b>		
I. Subscribed capital	13,720	13,805
II. Capital reserve	39,131	39,338
III. Other reserves	1	1
IV. Equity capital difference from currency translation	8	25
V. Valuation reserve for financial instruments	-94	-374
VI. Reserve for pensions	-126	-133
VII. Loss carry-forward	-11,370	-10,666
VIII. Annual net profit	704	985
<b>EQUITY CAPITAL ATTRIBUTABLE TO STOCKHOLDERS OF THE PARENT COMPANY</b>	<b>41,974</b>	<b>42,981</b>
Minority interest	286	366
<b>TOTAL EQUITY</b>	<b>42,260</b>	<b>43,347</b>
<b>LONG-TERM LIABILITIES</b>		
I. Pension provisions	595	566
II. Other provisions	1,921	1,674
<b>TOTAL LONG-TERM LIABILITIES</b>	<b>2,516</b>	<b>2,240</b>
<b>SHORT-TERM LIABILITIES</b>		
I. Tax provisions	43	42
II. Other provisions	715	765
III. Bank loans	43	33
IV. Received payments or orders	187	914
V. Trade accounts payable	2,343	1,919
VI. Liabilities with associated companies	15	17
VII. Other liabilities	3,424	4,270
<b>TOTAL SHORT-TERM LIABILITIES</b>	<b>6,770</b>	<b>7,960</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>51,546</b>	<b>53,547</b>

<b>CASH FLOW</b>	<b>2006</b>	<b>2007</b>
	<b>KEUR</b>	<b>KEUR</b>
<b>1, CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit before tax	736	1,493
Depreciation and amortization of intangible assets and plant, equipment and other fixed assets	2,646	3,060
Other expenses / income with no impact on cash	24	-263
Depreciation of financial assets	0	0
Profit / loss from disposal of long term capital	0	0
Profit / loss from disposal of securities	2	52
Increase / decrease in inventories	176	-139
Increase / decrease in trade receivables and other assets that cannot be allocated to investing or financing activities	-985	-1,888
Changes in provision	496	-221
Increase / decrease in trade accounts payable and other liabilities that cannot be allocated to investing or financing activities	-1,793	-654
Interest paid	-11	-7
Interest payments received	208	494
Income taxes paid	-136	-168
Income taxes received	155	177
	<b>1,518</b>	<b>1,936</b>
<b>2, CASH FLOW FROM INVESTMENT ACTIVITIES</b>		
Cash paid for investments in property, plant and equipment / intangible assets	-3,093	-3,647
Cash received from disposal of securities	0	0
Acquisition of consolidated companies, net of purchased cash	-1,308	-2,810
Cash receipts from aus Abgängen von Wertpapieren	2,253	6,109
Cash paid for investments in securities	-1,361	-1,965
	<b>-3,509</b>	<b>-2,313</b>
<b>3, CASH FLOW FROM FINANCING ACTIVITIES</b>		
Increase in share capital by edition of equity options	0	85
Allocation to capital reserve by edition of equity options	0	81
Auszahlungen in Finanzanlagevermögen	0	-750
Cash receipts from issuing short-term loans	0	-10
Amount paid out for redeeming loans	162	-33
	<b>162</b>	<b>-627</b>
<b>4, CASH AND CASH EQUIVALENTS AT END OF FISCAL YEAR</b>		
Cash-relevant changes in cash and cash equivalents (sum of 1 + 2 + 3)	-1,829	-1,004
Change in currency translation adjustment	-30	0
Change in financial resource fund caused by consolidation	735	0
Cash and cash equivalents at beginning of fiscal year	3,151	2,755
	<b>2,027</b>	<b>1,751</b>
<b>5, COMPOSITION OF CASH AND CASH EQUIVALENTS</b>		
Cash on hand	2,188	1,784
Bank liabilities due on demand	-161	-33
	<b>2,027</b>	<b>1,751</b>

# Facts and Figures Development of Group Equity as of 09/30/2007 and 09/30/2006 (IFRS)

DEVELOPMENT OF GROUP EQUITY	SUBSCRIBED CAPITAL	CAPITAL RESERVES	OTHER PROVISIONS	EQUITY DIFFERENCE FROM CURRENCY CONVERSION	RESERVE FOR FINANCIAL INSTRUMENTS	RESERVE FOR PENSIONS	CONSOLIDATED LOSS CARRY FORWARD	CONSOLIDATED DEFICIT / PROFIT	EQUITY CAP., ATTRIBUTABLE TO STOCKH. OF PARENT COMPANY	MINORITY INTEREST	TOTAL EQUITY	AUTHORIZED CAPITAL
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR
CONSOLIDATED EQUITY AS OF 12/31/2005	13,720	38,886	1	8	4	-139	-11,632	262	41,110	190	41,300	6,860
Transfer of 2005 consolidated loss to consolidated loss carry-forward							262	-262	0		0	
Total income entered directly in equity capital		116	-1	-30	-49				36		36	
Profit before tax 09/30/2006								557	557	24	581	
OVERAL RESULT OF THE PERIOD	0	116	-1	-30	-49	0	0	557	593	24	617	
CONSOLIDATED EQUITY ON 09/30/2006	13,720	39,002	0	-22	-45	-139	-11,370	557	41,703	214	41,917	6,860
CONSOLIDATED EQUITY ON 12/31/2006	13,720	39,131	1	8	-94	-126	-11,370	704	41,974	286	42,260	6,860
Profit before tax 2006 entered directly in accumulated deficit							704	-704	0		0	
Transfer to other Provisions									0		0	
Total income entered directly in equity capital				17	-280	-7			-270		-270	
Profit before tax 09/30/2007								985	985	80	1,065	
OVERAL RESULT OF THE PERIOD	0	0	0	17	-280	-7	0	985	715	80	795	
Edition of equity options to employees	85	81							166		166	
Stock-based payment		126							126		126	
CONSOLIDATED EQUITY ON 09/30/2007	13,805	39,338	1	25	-374	-133	-10,666	985	42,981	366	43,347	6,860

## **Declaration according to § 37y No. 1 WpHG**

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the group, and the interim management report of the group includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal opportunities and risks associated with the expected development of the group for the remaining months of the financial year.

Villingen-Schwenningen, November 21st, 2007

NEXUS AG  
Executive Board

***nexus/ag***  
*e-health solutions*

NEXUS AG, Auf der Steig 6, D-78052 Villingen-Schwenningen  
Telefon +49 (0)7721 8482 -0, Fax +49 (0)7721 8482-888  
[www.nexus-ag.de](http://www.nexus-ag.de), [info@nexus-ag.de](mailto:info@nexus-ag.de)